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Lipid raftsDeath receptor 6 (DR6/TNFRSF21) is a death domain-containing receptor of the TNFR superfamily with
an apparent regulatory function in hematopoietic and neuronal cells. In this study we document that DR6
is an extensively posttranslationallymodiﬁed transmembrane protein and thatN- andO-glycosylations of amino
acids in its extracellular part are mainly responsible for its approximately 40 kDa mobility shift in SDS
polyacrylamide gels. Site-directed mutagenesis conﬁrmed that all six extracellular asparagines are N-
glycosylated and that the Ser/Thr/Pro cluster in the “stalk” domain juxtaposed to the cysteine-rich domains
(CRDs) is a major site for the likely mucine-type of O-glycosylation. Deletion of the entire linker region between
CRDs and the transmembrane domain, spanning over 130 amino acids, severely compromises the plasma
membrane localization of DR6 and leads to its intracellular retention. Biosynthetic labeling with radiolabeled
palmitate and side-directed mutagenesis also revealed that the membrane-proximal Cys368 in the intracellular
part of DR6 is, similarly as cysteines in Fas/CD95orDR4 ICPs, S-palmitoylated. However, palmitoylation of Cys368
is apparently not required for DR6 targeting into Brij-98 insoluble lipid rafts. In contrast, we show that N-
glycosylation of the extracellular part might participate in directing DR6 into these membrane microdomains.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Death receptor-6 was till recently one of the few “orphan”
receptors of the TNFR superfamily. TNFR receptors are recognized
by the presence of 1–4 cysteine-rich domains in their extracellular
parts. Together with their ligands, predominantly expressed by
hematopoietic cells, they participate in regulating the proliferation,
survival or apoptosis of various, not exclusively hematopoietic, cells
[1]. DR6 was identiﬁed as a new member of the death receptor sub-
family, which is distinguished by the presence of an α-helical
structural motif called the death domain in the intracellular part [2].
Some of the death receptors, such as Fas/CD95 or the TRAIL receptors
TRAIL-R1/DR4 and TRAIL-R2/DR5, are potent inducers of apoptosis,
while others such as DR3 or EDAR participate in the regulation of T cell
activation or play a role during development [3,4].
Cysteine-rich domains of DR6 as well as its death domain and the
C-terminal α-helical CARD-like region are highly conserved in
vertebrates from zebraﬁsh to humans. Overexpression of DR6 in
some cell lines leads to apoptosis and/or to the activation of NFκB and
stress kinases of the JNK/SAPK family [2,5,6].
The unavailability of theDR6 ligand has restricted studies examining
DR6 function mainly to analyses of DR6 knockout mice. DR6 is not,g and Apoptosis, Institute of
epublic, Vídeňská 1083, 14220
420 241062471.
ra).
l rights reserved.similarly as other death receptors, required for the development or
survival of mouse embryos, but its genetic inactivation enhanced the
proliferation of CD4+ T cells and the production of Th2 cytokines [7,8].
Similarly, DR6-deﬁcient B lymphocytes were hyperproliferative follow-
ing various stimuli and showed attenuated stimulation-induced cell
death [9]. The enhanced activation of DR6-deﬁcient T and B cells was
also reﬂected in more severe graft-versus-host disease induced by
allogenic bone marrow transplantation into irradiated recipient mice
[10]. The development and progression of autoimmune or allergic
responses, such as experimental autoimmune encephalomyelitis or
allergic airway inﬂammation, is attenuated in DR6 knockout mice
[11,12]. However, recently the cleaved off extracellular part of APP or
APLP2 proteins was reported to function as a DR6 ligand and to trigger
DR6-dependent death of neurons and/or pruning of their axons [13].
DR6 expression is alsomarkedly increased in several human tumor-
derived cell lines. Increased DR6 expression in PC3 or DU145 prostate
carcinoma cells is accompanied by enhanced NFκB signaling and
increased BclXL expression [14]. In another prostate carcinoma cell
line, LnCAP, DR6 expression was induced in a TNFα/NFκB-dependent
manner. Increased DR6 expression on tumor cells could have functional
consequences asmatrixmetalloproteinase-14 is able to cleaveDR6 from
the cell surface, and the shed extracellular part of DR6was suggested to
attenuate the in vitro differentiation of monocytes into dendritic cells,
which can contribute to tumor evasion from the immune system [15].
In this communication we document that DR6 is S-palmitoylated on
itsmembrane-proximal cysteine and its extracellular part is extensively
N- and O-glycosylated. We show that these DR6 modiﬁcations are
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localization of DR6.
2. Materials and methods
2.1. Plasmids and antibodies
The coding region of human DR6 was ampliﬁed by RT-PCR from
total HeLa RNA, prepared by TRIZOL Reagent (Invitrogen) according to
the manufacturer's instructions. The PCR product was cloned into
pBluescript SK vector (Stratagene) and sequenced. For bacterial
expression, the DR6 intracellular fragment corresponding to amino
acids 371–655 was cloned into the pET-15b expression vector
(Novagen), generating a construct with an N-terminal histidine tag.
For expression in eukaryotic cells, DR6 cDNA was subcloned into the
pcDNA3 vector (Invitrogen).
Site-directed mutagenesis was used to replace the asparagine
residues of human DR6 at positions 82, 141, 252, 257, 287 and 289
with glutamines, the cysteine residue at position 368 with valine, and
for internal deletions of the DR6 linker region (amino acids 212–349).
Mutagenesis was performed with the QuickChange Site-Directed
Mutagenesis Kit (Stratagene) with the primers summarized in Suppl.
Table 2. Multiple point mutants were prepared by consecutive site-
directed mutagenesis.
Mousemonoclonal antibodies against the extracellular part of DR6
were prepared using the standard techniques from splenocytes of
mice immunized with the chimeric fusion protein of the extracellular
part of DR6 (amino acids 42–335) and the Fc portion of human
immunoglobulin IgG1 (Alexis). To raise mouse monoclonal or rabbit
polyclonal antibodies directed against the intracellular domain of
DR6, a puriﬁed His-tagged fragment of human DR6 (amino acids 370–
655) expressed in E. coli was used as an immunogen. For some
experiments, rabbit polyclonal antibody directed against the N-
terminal peptide of mature DR6 (amino acids 42–56) was used as a
control (BD PharMingen). Rabbit polyclonal anti-CD59 antibody
(MEM-43) was kindly provided by Prof. V. Horejsi.
2.2. Cell culture, transfections and down-regulation of DR6 expression
The human T cell lines Jurkat and HuT78, the B cell lines KM3 and
IM-9, the myeloid cell lines THP-1 and HL60 and the prostate
carcinoma cell line LnCAP were maintained in RPMI1640 medium
supplemented with 10% heat-inactivated fetal calf serum. The human
embryonic kidney cell lines HEK293 and HEK293FT, human immor-
talized keratinocytes NCTC and the cervical-carcinoma cell line HeLa
were maintained in Dulbecco's modiﬁed Eagle's medium supplemen-
ted with 10% FCS. NCTC cells were provided by Dr. L. LoMuzio; all
other cell lines were obtained from either ATCC or from the cell line
collection of the Institute of Molecular Genetics.
Transfections of HeLa or HEK293 cells were performed using
LF20020 (Invitrogen) or Fugene HD (Roche), as described by the
manufacturer. Two independent DR6 siRNA oligonucleotides
(Ambion) or control luciferase siRNA (Dharmacon) were used for
lipofectamine RNAiMAX-mediated down-regulation of DR6 expres-
sion in NCTC cells (Suppl. Table 1). TNFα used for the treatment of
LnCAP cells was purchased from R&D Systems.
2.3. Immunoprecipitation
The cells were harvested, washed with phosphate-buffered saline
and lysed in ice-cold lysis buffer (1% NP-40, 20 mM Tris Cl pH 7.5,
100 mMNaCl, 50 mMNaF, 10 mMEDTA, 1 mMNa3VO4, 10% glycerol),
supplemented with protease inhibitors (Complete® protease inhib-
itor cocktail, Roche). After solubilizing for 30 min on ice, the lysate
was pre-cleared by centrifugation at 16,000×g for 30 min. The
resulting supernatant was incubated either with anti-DR6 mAbcovalently coupled to CNBr-activated Sepharose beads (GE Health-
care) or with rabbit anti-DR6 antibodies bound to protein A/G
Sepharose (Pierce) for 1 h at 4 °C. After three washes with 10 volumes
of the lysis buffer, the immunoprecipitates were directly eluted with
Laemmli sample buffer and analyzed byWestern blotting using either
rabbit or mouse anti-DR6 antibodies.
2.4. Confocal microscopy and ﬂow cytometry
HeLa cells transfected with DR6 mutants and grown on cover slips
were permeabilized in a−20 °Cmethanol bath for 10 min and then for
5 s in cold acetone. Afterwashing in PBS the slideswere incubatedwith
anti-DR6mAb for 30 min, followed by 30 min incubationwith 4 µg/ml
Alexa488-conjugated goat anti-mouse IgG (Molecular Probes). The
samples were mounted in moviol with DRAQ5® (Axxora) and viewed
with a Laserscan confocal microscope (Leica TCS SP).
The cells for ﬂow cytometry analysis were harvested and
incubated on ice with a blocking solution (PBS+0.2% gelatine and
0.1% sodium azide=PBS-GA) containing 20% heat-inactivated human
serum for 10 min. After blocking, the sampleswere incubated on ice in
PBS-GA with anti-DR6 mAb (5 µg/ml) for 30 min, followed by a 30-
min incubation on ice in PBS-GA with 4 µg/ml phycoerythrin-
conjugated goat anti-mouse IgG1 (SouthernBiotech). After ﬁnal
washing, the surface expression of DR6 on living cells (Hoechst33258
low) was analyzed by ﬂow cytometry on a LSRII (BD Biosciences).
2.5. Cell treatments and endoglycosidase digestions
The cells were cultured overnight in the presence of the N-
glycosylation inhibitor tunicamycin (ﬁnal concentration 5 μg/ml,
Sigma), or in the presence of 2 mM benzyl-2-acetamido-2-deoxy-α-
D-galactose (benzyl-O-GalNAc, Sigma), an inhibitor of the formation
of N-acetylgalactosamine-O-Ser/Thr-linked glycoconjugates, or alter-
natively in the presence of 200 μM 2-bromopalmitate (Sigma), a
palmitate analogue and an inhibitor of S-palmitoylation.
To perform endoglycosidase digestions, the immunoprecipitated
DR6 was denatured and eluted from the anti-DR6-Sepharose beads by
incubation in 1× Glycoprotein Denaturing Buffer (New England
Biolabs) at 95 °C for 10 min. N-linked glycans were cleaved off with
PNGase F (N-glycosidase F, NEB) and O-linked oligosaccharides with
endo-α-N-acetylgalactosaminidase (O-glycosidase, NEB) and neur-
aminidase (NEB) by 20 h incubation at 37 °C in 1× G7 Reaction Buffer
(NEB) supplemented with 1% NP40.
2.6. Biosynthetic labeling with [3H]palmitate
HEK293FT cells (2×107cfu) were transfected with DR6 expression
plasmids, starved at 37 °C in 50 ml of plain RPMI1640 medium for 1 h
and then 0.5mCi of radiolabeled palmitate ([9,10(n)-3H]palmitic acid,
speciﬁc activity 30–60 Ci/mmol; PerkinElmer Life and Analytical
Sciences) was added. After 3 h at 37 °C the cells were washed and
solubilized in a 1% NP40 lysis buffer, and the postnuclear supernatant
was used for immunoprecipitation followed by SDS-PAGE. The wet gel
was treated with Amplify solution (GE Healthcare) according to the
manufacturer's recommendations, dried, and subjected toﬂuorography.
2.7. Density gradient ultracentrifugation
HEK293 cells (2×107cfu) transfected with appropriate DR6 (wt or
mt) expression plasmids or NCTC cells (108cfu) were harvested,
washedwith PBS and lysed in 0.5 ml of ice-cold lysis buffer (1% Brij98,
20 mM Tris Cl pH 8.2, 100 mM NaCl, 50 mM NaF, 10 mM EDTA, 1 mM
Na3VO4), supplemented with protease inhibitors (Complete® prote-
ase inhibitor cocktail, Roche), on ice for 30 min. 0.5 ml of the lysate
was then mixed at a 1:1 ratio with ice-cold 80% (wt/vol) sucrose
diluted in lysis buffer and transferred into 5-ml ultracentrifugation
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buffer and ﬁnally with 0.5 ml of sucrose-free lysis buffer. After
centrifugation at 50,000 rpm in a MLS-50 rotor (cca 268,000×g;
Beckman Coulter) for 18 h at 4 °C, 0.7 ml fractionswere collected from
the top to the bottom of each tube and analyzed by Western blotting.
3. Results
3.1. DR6 is expressed in two forms of apparent molecular masses 90 kDa
and 110 kDa
Although from mouse knockout data the death receptor-6 is
thought to have a dampening function in regulating the immune
response, it was reported to be also expressed in some human, mainly
prostate-derived, tumor cell lines [14]. In our screening for additional
cells that might express DR6, we reproducibly observed in the cell
lysates of all analyzed cell lines, of both hematopoietic and non-
hematopoietic origin, a 68–70 kDa band (termed p70) that would
correspond to the predictedmolecular mass of human DR6 (68 kDa or
72 kDa including the putative signal peptide). This band was stained
with polyclonal antibodies that map both to the N-terminal peptide
(amino acids 42–56, e.g. Abcam ab8417) and to the cytoplasmic part
of DR6 (amino acids 371–655, e.g. Abcam ab47180 or our own rabbit
polyclonal antibody, marked by asterisks in Fig. 1A). However, wild-
type DR6 exogenously expressed in HEK293 cells predominantly
yielded higher molecular weight bands of apparent molecular masses
85–90 kDa (termed p90) and 105–110 kDa (termed p110), but not
the p70 band (not shown). In addition, using our own monoclonal
antibodies raised against the extracellular part of DR6, wewere able to
immunoprecipitate from some cell lines (KM3, Jurkat, NCTC) the
110 kDa and, to a lesser extent, the 90 kDa forms of DR6 (marked by
arrows in Fig. 1A) but almost none of the 70 kDa protein. In order to
resolve this uncertainty regarding the expression and apparent
molecular weight of DR6, we also determined the cell surface
expression of DR6 in the tested cell lines by ﬂow cytometry
(Fig. 1B) and quantiﬁed the relative amount of DR6 mRNA by real-
time qRT-PCR (Suppl. Fig. 1); these results closelymatched those from
the immunoprecipitation of the DR6 110/90 kDa forms, suggesting
that the p70 protein is not the major functional form of DR6 and its
real identity is uncertain (at least in cells that we used in this study).
These ﬁndings are supported by two other independent lines of
experimental evidence. First, siRNA-mediated knockdown of DR6
mRNA in NCTC cells led to the disappearance of only the 110/90 kDa
forms and not the 70 kDa band (Fig. 1C). Second, according to the
published observation that TNFα induces the expression of DR6
through the activation of NF-κB [14], the p90 and p110 DR6 forms
were strongly upregulated by the cultivation of LnCAP prostate
carcinoma cells in the presence of TNFα, whereas the expression of
the p70 protein again remained unaffected (Fig. 1D). Summing these
data together, it appears that not the calculated 70 kDa form but the
110 kDa and, to a lesser extent, the 90 kDa bands are the major if not
the only naturally expressed forms of DR6.
3.2. DR6 is a palmitoylated protein with an extensively glycosylated
extracellular part
The signiﬁcant difference between the predicted (70 kDa) and
actual (110 kDa and 90 kDa) molecular masses of DR6 suggests the
presence of possible posttranslational modiﬁcation(s) that modulates
its relative mobility in SDS-PAGE. These modiﬁcations most probably
reside in the extracellular region of DR6 as the deletion mutant
lacking most of the DR6 intracellular part modulated its relative
mobility in SDS-PAGE in a similar way as did wild-type DR6 (not
shown). The TNFR superfamily members are often subjected to
glycosylation, and thereforewe searched the extracellular sequence of
DR6 for potential N- and mucin-type O-glycosylation sites usingNetNGlyc 1.0 and NetOGlyc 3.1 predictions, respectively [16]. Human
DR6 contains six potential N-linked oligosaccharide chain sites
(Asn82, Asn141, Asn252, Asn257, Asn278 and Asn289) and multiple
potential O-linked oligosaccharide chain sites with a greater prefer-
ence for Thr213, Thr221, Thr227, Thr238, Thr245 and Thr254 (Suppl.
Fig. 2A).
For assessing the relative contribution of N- and O-glycosylation, we
combined cell treatment with known inhibitors of N- and O-glycosyl-
ation, tunicamycin and benzyl-2-acetamido-2-deoxy-α-D-galactose
(benzyl-O-GalNAc) respectively, with the in vitro deglycosylation of
the immunoprecipitated DR6. For in vitro enzymatic deglycosylation, we
used either PNGase F (N-glycosidase F), which removes N-linked
oligosaccharides by cleaving between the innermost GlcNAc and Asn
residues, or a mixture of neuraminidase and endo-α-N-acetylgalactosa-
minidase (O-glycosidase), which removes the terminal sialic acid
residues or desialyated core 1 andcore 3O-linkeddisaccharides attached
to Ser/Thr residues, respectively.
Cell treatment with glycosylation inhibitors as well as enzymatic
deglycosylation, either alone or in various combinations, led to a distinct
but not complete reduction of the apparent molecular mass of DR6
(Fig. 2A). PNGase F and tunicamycin interventions signiﬁcantly
enhanced the mobility of both p110 and p90, indicating that these
formsofDR6 containN-linkedoligosaccharides (Fig. 2A, lanes 5 and 13).
In contrast, the O-glycosylation inhibitor benzyl-O-GalNAc and in vitro
O-linked deglycosylation of the immunoprecipitated DR6 partly
enhanced the mobility of only the p110 form, which argues for the
presence of O-linked oligosaccharides only in the p110, presumably a
more mature form of DR6 (Fig. 2A, lanes 4 and 7). Subsequent usage of
both of these de-O-glycosylation interventions shifted mobility of the
p110 form even further implicating non-overlapping modes of the
action of these reagents (Fig. 2A, lane 8). Both enzymatic N-linked
deglycosylation and tunicamycin treatment shifted the mobility of the
p90 band to approximately 70 kDa, suggesting that p90 might be an N-
only-glycosylated intermediate form of DR6 (Fig. 2A, lanes 5 and 13).
The combination of tunicamycin, benzyl-O-GalNAc and O-glycolytic
enzymes enhanced DR6 gel migrationmost efﬁciently (Fig. 2A, lanes 18
and 20). Thus, it appears that the p110 form of DR6 is both N- and O-
glycosylated and that these glycosylations largely account for the
apparent approximate 40 kDa shift in its calculated mobility.
Glycosylation prediction analysis points to six potentially N-
glycosylated asparagines in the DR6 extracellular part and a cluster of
O-glycosylated serines and/or threonines between amino acids 212
and254of theDR6precursor (Suppl. Fig. 2A). Individual and consecutive
mutagenesis of all asparagines (starting from Asn82) to glutamines in
the DR6 extracellular part revealed that each of them is N-glycosylated
(gradual shift in the apparent molecular weight), and the migration of
the ultimate DR6 mutant reﬂected the DR6 mobility in tunicamycin-
treated cells (Fig. 2B). These data lead us to conclude that all six
asparagines in the extracellular part of DR6 are N-glycosylated.
As Fas/CD95 and TRAIL-R1/DR4 were recently described as
palmitoylated proteins targeted to lipid rafts [17,18], we asked
whether this membrane domain targeting- and trafﬁcking-related
posttranslational modiﬁcation can also occur in DR6. Human and
mouse DR6 proteins contain a conserved cysteine residue in the
membrane-proximal intracellular region (Cys368 in the human DR6
precursor), which could be potentially S-palmitoylated (Suppl.
Fig. 2C). HEK293FT cells were transfected with DR6 and DR6
(C368V) mutants, cultured in medium containing radioactive [3H]
palmitate, lysed and immunoprecipitated with DR6 antibody. Auto-
radiography of the SDS-PAGE-separated immunoprecipitates revealed
that [3H]palmitic acid is incorporated into DR6 and slightly more
efﬁciently also into DR6(6xNQ) mutant but not into the DR6(C368V)
mutant, indicating that Cys368 is indeed being palmitoylated (Fig. 2C,
lanes 1–4). Speciﬁcity of DR6 palmitoylation was further conﬁrmed
using a competitive palmitoylation inhibitor 2-bromopalmitate (Fig. 2C,
lanes 6, 7).
Fig. 1. Death receptor 6 is expressed at the cell surface of various cell lines as a 110 kDa protein. A. The indicated cell lines (approximately 3×107cfu) were lysed and DR6 was either
immunoprecipitated from the lysate with anti-DR6(ECP) mAb (lower panel) prior to Western blotting or the cell lysate was directly analyzed by Western blotting using rabbit anti-
DR6(ICP) antibodies (upper panel). B. Cell surface expression of DR6 on these cell lines was analyzed by ﬂow cytometry using anti-DR6(ECP) mAb. C. NCTC cells were transfected
with control luciferase or two different DR6 siRNAs, and DR6 from their cell lysates was immunoprecipitated with anti-DR6(ECP) mAb and/or analyzed by anti-DR6(ICP) Western
blotting. D. LnCAP prostate carcinoma cells were treated with TNFα (20 ng/ml) for the indicated time periods then lysed, and DR6was immunoprecipitated with anti-DR6(ECP) mAb
and revealed by Western blotting.
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the transmembrane part is required for the plasma membrane localization
of DR6
Having established the presence of multiple posttranslational
modiﬁcations in DR6, we were eager to uncover their function. Inaddition to the already prepared mutants in the N-glycosylation and
palmitoylation sites, we aimed to target the O-glycosylation sites as
well. In contrast tomost of its TNFR kin, DR6 harbors an unusually long
(approximately 130 amino acids) linker region between CRDs and the
transmembrane domain, which also contains the majority of the
predicted mucin-type O-linked oligosaccharide chain sites, mainly
Fig. 2. DR6 is an extensively N- and O-glycosylated and S-palmitoylated protein. A. DR6-transfected HEK293FT cells were cultured with 5 μg/ml of tunicamycin and/or 2 mM benzyl-
O-GalNAc for 15 h, lysed and then DR6 immunoprecipitated with mouse monoclonal anti-DR6(IC) antibody was, where indicated, subjected to glycolytic treatment and analyzed by
Western blotting using rabbit anti-DR6(EC) polyclonal antibodies (Pharmingen). B. HEK293FT cells were transfected with plasmids encoding consequent DR6 (N→Q) mutants,
lysed and analyzed by Western blotting with anti-DR6 rabbit pAbs. The mutated Asn in individual DR6 mutants are displayed in the inset. C. HEK293FT cells were transfected with
the indicated DR6 expression plasmids and biosynthetically labeled with [3H]palmitate, then the DR6 in the cell lysates (upper panel) or the rabbit anti-DR6(IC) immunoprecipitates
(middle and lower panels) were analyzed by SDS-PAGE followed by Western blotting with anti-DR6 antibodies and ﬂuorography.
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Similarly clustered Ser-/Thr-/Pro-rich sequences, called “stalk
regions”, were found in some other TNFR receptors (as TNFR2, CD30
or NGFR) and are also predicted to be extensively O-glycosylated
(Suppl. Table 1). As multipleO-glycosylation sites are predictedwith a
higher probability mainly in the stalk region, we targeted it as well as
its complementary part and the entire linker region for deletion. The
complete set of DR6 mutants (Fig. 3A) was used for analyzing their
effect on DR6 plasma membrane localization. The expression and
proper folding of the DR6 variants transfected into HEK293FT cells
were conﬁrmed by immunoprecipitation with conformation-speciﬁc
monoclonal antibodies to DR6 and by Western blotting. All proteins
were expressed and, when applicable as revealed by tunicamycin
treatment, also N-glycosylated. Mobility in SDS-PAGE and the
membrane localization of the S-palmitoylation-deﬁcient mutant DR6
(C368V) were not different from wild-type DR6, and the fully N-
glycosylation-deﬁcient mutant DR6(6xNQ) was also localized at the
plasma membrane (Fig. 3). Deletion of the stalk region (amino acids
212–254) led to a large reduction in the amount of fully modiﬁed DR6
corresponding to the p110 form inwild-type DR6 and to the predictedshift in the mobility of the N-only-glycosylated form corresponding to
the p90 form in wild-type DR6 (Fig. 3B, lanes 11–12). In contrast,
removing the complementing sequence in the linker domain (amino
acids 255–348) did not affect additional posttranslational modiﬁca-
tions of DR6, arguing for the stalk domain as the major likely O-
glycosylated region in the extracellular part of DR6 (Fig. 3B, lane 11).
Notably, the efﬁcient DR6/Δ255–348 presentation at the plasma
membrane (Fig. 3D, compare the histograms of wild-type DR6 and
DR6/Δ255–348) can be related to its enhanced O-glycosylation. As
predicted, DR6/Δ212–348 contains just two N-glycosylation sites, and
upon tunicamycin treatment it migrates in agreement with the
calculated molecular weight of approximately 55 kDa (Fig. 3B, lanes
15–16). However, in contrast to the partial deletion mutants,
removing the entire linker region from the DR6 extracellular part
signiﬁcantly affected the behavior of this DR6 mutant. It was
drastically less mobilized to the plasma membrane than wild-type
DR6 or the partial deletion linker region mutants and remained
stackedmost probably in the Golgi system (Fig. 3C, D). Thus, the linker
region (or its major part) is required for the proper transport of DR6 to
the plasma membrane.
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targeting to lipid rafts
The palmitoylation of Cys368 juxtaposed to the transmembrane
region and the targeting of palmitoylated Fas/CD95 and TRAIL-R1 to
lipid rafts raised a question about the plasmamembrane sublocalization
of DR6. To analyze in which membrane compartment endogenous DR6
resides, human keratinocyte-derived cells NCTC (the cell line with the
highestDR6expression thatwedetected)were lysed inBrij98detergent
and subjected to sucrose gradient ultracentrifugation. The p110 DR6
form was mainly detected in the same fractions close to the top of the
gradient as was CD59, a well established marker of detergent-resistant
glycosphingolipid-enriched microdomains (lipid rafts) (Fig. 4A). In
contrast, the p70 protein was almost exclusively present in the dense
non-raft fractions at the bottom of the gradient. To evaluate the role of
DR6 S-linked palmitoylation, wild-type DR6 and a S-palmitoylation-
deﬁcient DR6(C368V) mutant were ectopically expressed in HEK293
cells and the cell lysates were subjected to sucrose gradient ultracen-
trifugation. In contrast to endogenous DR6, only part of the transfected
wild-type DR6 was localized to the light lipid raft fractions (Fig. 4B,
upper panel). The distribution of theDR6(C368V)mutant in the sucrose
gradient fractions did not notably differ from that of wild-type DR6,
arguing for a non-essential role of Cys368 palmitoylation in the lipid raft
targeting of DR6 (Fig.4B, middle panel). In addition, the treatment of
NCTC cells with 2-bromopalmitate, an inhibitor of S-linked-palmitoyla-
tion, did not affect its localization to the light lipid raft fraction (Fig. 4C).
Thus, S-palmitoylation of DR6 is apparently not essential for DR6
targeting to the lipid rafts.
Several recent publications point to N-glycosylation as a possible
targetingmarkof transmembranereceptors to lipid rafts [19]. In support
of these ﬁndings, we also observed N-glycosylation-dependent target-
ing of transfected DR6 into lipid rafts and discovered that the locali-
zation of the N-glycosylation-deﬁcient DR6(6xNQ) mutant in the light,
lipid raft-containing fractions was severely reduced (Fig. 4B, lower
panel). However, the treatment of NCTC cells with tunicamycin,
an inhibitor of N-glycosylation, did not inﬂuence the localization
of DR6 to the light lipid raft fractions, arguing against a potential role
of N-glycosylation in the mobilization of DR6 into lipid rafts (Fig. 4C,
lower panel). Thus, the possible role of N-glycosylation in the targeting
of DR6 into lipid rafts remains unresolved and should be further
investigated.
A recently published report proposed a potential role of DR6 in the
differentiation of monocytes into immature dendritic cells [15]. The
authors, using recombinant, in insect cell-produced DR6-Fc fusion
protein, partially suppressed the IL-4+GM-CSF-induced expression of
the differentiationmarker CD1a. We used this assay for evaluating the
potential role of DR6 N-glycosylation. Monocytes from two different
donors were differentiated into immature dendritic cells, and this
differentiation could be suppressed by recombinant DR6-Fc fusion
protein produced in a baculoviral system (Suppl. Fig. 3A). However,
using either our recombinant or other commercially available DR6-Fc
fusion protein produced in HEK293FT cells, we could not reproduce
inhibition of IL-4+GM-CSF-induced monocyte differentiation im-
posed by the DR6-Fc produced in insect cells (Suppl. Fig. 3A). Such
unexpected differences between these fusion proteins prompted us to
compare their properties, including their mobility in SDS-PAGE. As
shown in Suppl. Figs. 3B, C the baculovirally-produced DR6-Fc, despite
its 15 amino acid extension in the DR6 extracellular part, migratedFig. 3. The extracellular linker region between cysteine-rich domains and the transmembra
view of DR6 mutants; yellow—signal peptide, red—cysteine-rich domains, violet—transmem
(6xNQ)—N-glycosylation-deﬁcient mutant. B. Wild-type and mutants of DR6 were expresse
blotting. C. HeLa cells were transfected with the indicated DR6 expression plasmids, and the c
(ICP) polyclonal antibodies. D. HEK293FT cells were transfected with DR6 expression plasmid
ﬂow cytometry. (red histogram represents cells stained only with the secondary antibody amainly due to the absence of most of the N-linked glycosylation in SDS
polyacrylamide gel faster than DR6-Fc expressed in human cells.4. Discussion
Death receptor-6 belongs among the longest (number of amino
acids) and also the least characterized receptors from the TNFR family.
Apart from the common cysteine-rich domains and the membrane-
proximal death domain, it also contains an unusually long linker
region in its extracellular part and the intracellular C-terminal CARD-
like domain [20]. In this communication we show that DR6 is also a
heavily posttranslationally modiﬁed receptor and that extensive and
complex N- and O-glycosylation and potentially other modiﬁcations
of its extracellular part are mainly responsible for a 40 kDa mobility
shift in DR6 polyacrylamide gel migration, exceptional among TNFR
superfamily members. We found that both transfected and endoge-
nous DR6 is mainly expressed in 2 forms—the major N- and likely O-
glycosylated p110 protein and the minor N-only-glycosylated form
p90, which most probably represents a DR6 precursor transiently
formed mainly upon the ectopic overexpression of DR6. In contrast to
the clear-cut assessment of N-glycosylated sites in the extracellular
part of DR6, even combined enzymatic and inhibitor-based treatment
targeting mucin-type O-glycosylation led only to an approximate
25 kDa drop in the apparent molecular weight (Fig. 2A, lane 8),
pointing to either the incomplete inhibition and/or accessibility of O-
linked oligosaccharide chains or the presence of other posttransla-
tional modiﬁcations such as xylose-O-Ser-linked or N-acetylglucosa-
mine-O-Ser-linked glycosylation.
Glycosylation of amino acids in the extracellular parts of plasma
membrane proteins, including the receptors of the TNFR family, can
affect the folding, trafﬁcking, localization and function of these
receptors [21]. Defects in the N-glycosylation of some plasma
membrane receptors such as the prostaglandin E2 receptor, the α
chain of FcεRI, the dopamine D5 receptor, the HLD receptor SR-BI or
the TRPM8 cation channel were reported to affect their folding,
trafﬁcking to the cell surface or targeting to submembrane domains
such as lipid rafts [19,22–25]. In contrast to these receptors, we found
that N-glycosylation of DR6 is apparently not required for its plasma
membrane targeting as both a N-glycosylation-deﬁcient DR6 mutant
and DR6 from tunicamycin-treated cells were still transported to and
localized at the cell surface. Also, our N-glycosylation-deﬁcient DR6-
Fc fusion protein was, in contrast to the N-glycosylation mutant of
TNFR1, transported to the cell surface of HEK293FT cells and secreted
(not shown and [26]). However, N-glycosylation deﬁcient DR6 still
maintains a high degree of N-glycosylation-independent posttransla-
tional modiﬁcations, such as O-glycosylation, that can perhaps
compensate for the loss of hydrophilicity and ensure proper folding
and transport to the cell surface. Moreover, these results clearly show
that N-glycosylation per se is not required for these additional
posttranslational modiﬁcations.
In contrast to N-glycosylation, which is present partially in the
cysteine-rich domains of DR6, mucin-type O-glycosylation (and other
possibleposttranslationalmodiﬁcations inDR6p110protein) take place
exclusively in the linking the region between CRDs and the transmem-
brane part. Similar linker regions containing O-glycosylation-rich
“stalk” domains are present in some other TNFR superfamily members
such as CD30, NGFR or TNFR2. O-linked glycosylation of serines and/orne domain of DR6 is essential for plasma membrane targeting of DR6. A. Graphical bar
brane region, blue—death domain; DR6(C368V)—palmitoylation-deﬁcient mutant, DR6
d in HEK293FT cells with or without tunicamycin treatment and analyzed by Western
ellular localization of DR6was analyzed by confocal microscopy using puriﬁed anti-DR6
s, stained with anti-DR6(ECP)mAb and the DR6 cell surface expressionwas analyzed by
nd the blue one cells stained with anti-DR6(ECP) mAb).
Fig. 4. N-glycosylation but not S-palmitoylation might participate in the targeting of DR6
into lipid rafts. A. NCTC cell lysate solubilized in Brij98 buffer was subjected to sucrose
density gradient ultracentrifugation, and the fractions were analyzed byWestern blotting
using anti-DR6 or anti-CD59 (control marker of lipid rafts) antibodies. B. HEK293 cells
were transfected with DR6 expression plasmids, solubilized in Brij98 buffer and analyzed
as described in A. C. NCTC cells with or without 2-bromopalmitate or tunicamycin
treatment were solubilized in Brij98 buffer and analyzed as described in A.
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orientation of CRDs towards the respective interacting ligand. In
contrast to DR6, deletion of the linker region in NGFR did not affect
the transport of NGFR to the plasma membrane but changed its apical-basolateral targeting in polarized cells [27,28]. Thus, the linker region
might contain a sequential or structural motif required for the proper
sortingof transmembraneproteins and/or, aswe found forDR6, for their
effective transport to the cell surface. DR6 lacking the entire linker
region most probably remains stacked in the Golgi system.
In addition to plasma membrane targeting and localization, the
glycosylation of DR6 can potentially regulate the interaction of DR6
with its recently described ligands APP or APLP2 [13]. Glycosylation
was shown to both attenuate the interaction of FGFR1with FGF-2 [29]
and to enhance the ligand binding of the 5-HT3A receptor [30]. We
also found apparent functional differences between insect and human
cell-produced DR6-Fc proteins in respect to modulation of monocyte
differentiation to dendritic cells. This discrepancy could be related to
evident differences in N-linked glycosylation of the recombinant
receptors produced in insect versus human cells (Suppl. Fig. 3C),
hinting either at the functional signiﬁcance of DR6 glycosylation
status requirements for interaction with its ligand (possibly APLP2,
which is expressed in human CD14+ monocytes, data from GNF
Symatlas at http://symatlas.gnf.org/SymAtlas/) or at a non-speciﬁc
off-target effect of the insect cell-produced, and possibly differently
folded DR6-Fc. Thus, the role of posttranslational modiﬁcations in the
interaction between DR6 and its ligand/-s remains to be explored.
An additional posttranslational modiﬁcation present in Fas/CD95
and TRAIL-R1, but not in TNFR1 or TRAIL-R2, is S-palmitoylation of the
membrane-proximal cysteine(s), which is apparently required for
their association with lipid rafts and effective pro-apoptotic signaling
[17,18]. We proved that similarly as these death receptors, DR6 is S-
palmitoylated at the membrane-proximal Cys368 residue in the
intracellular region. In cells expressing high levels of DR6 such as
NCTC and PC3, the majority of DR6 is associated with the light, Brij98-
insoluble (but NP40-soluble) lipid raft-containingmembrane fraction.
However, neither the treatment of cellswith a palmitoylation inhibitor
nor the usage of a DR6 point mutant lacking S-palmitoylation affected
the subcellular localization of DR6, suggesting that other motifs might
participate in DR6 targeting to Brij98-insoluble lipid rafts. Among
possible lipid raft-targeting mechanisms could be the death domain-
mediated targeting shown for TNFR1, the extracellular glycosphingo-
lipid-binding motif found in Fas/CD95 or N-linked glycosylation-
assisted targeting as shown for the TRPM8 cation channel [19,31,32].
Our N-glycosylation-deﬁcient mutant of DR6 was inefﬁciently
targeted to lipid raft fractions, suggesting a positive effect of N-
glycosylation on DR6 localization to lipid rafts. However, as the
inhibition of endogenous DR6 N-glycosylation in NCTC cells by
tunicamycin did not signiﬁcantly affect the distribution of DR6 in the
lipid raft fractions, we cannot unambiguously attribute to the N-
glycosylation of DR6 its lipid raft-targeting mark and surely other, yet
unknown concurrent mechanisms can take over, when the N-linked
glycosylation of DR6 is disabled in e.g. tunicamycin-stressed cells.
Nevertheless, the lipid raft localization of DR6 could be important for
the regulation and outcome of DR6 signaling. The lipid raft localization
of TNFR1 was proven to be essential for the activation of NFκB,
p42MAPK or RhoA signaling in a cell-speciﬁc manner [33–35].Acknowledgements
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